Belle, R., F. Baska, Z. Orfi, C. Szantai-Kis, A. Sipos, N. Breza, G. Borbely, K. Penzes, L. Orfi and G. Keri: Characterization of p53 activator compounds which inhibit a survival factor kinase as well. In: FEBS Journal 279, Suppl. 1 Sp. Iss., 179-179 (2012).
Keri, G., L. Orfi, D. Eros, B. Hegymegi-Barakonyi, C. Szantai-Kis, Z. Horvath, F. Waczek, J. Marosfalvi, I. Szabadkai, J. Pato, Z. Greff, D. Hafenbradl, H. Daub, G. Muller, B. Klebl and A. Ullrich: Signal transduction therapy with rationally designed kinase inhibitors. In: Current Signal Transduction Therapy 1, 1, 67-95 (2006).
Szantai-Kis, C., I. Kovesdi, D. Eros, P. Banhegyi, A. Ullrich, G. Keri and L. Orfi: Prediction oriented QSAR modelling of EGFR inhibition. In: Current Medicinal Chemistry 13, 3, 277-287 (2006).
Kéri, G., Z. Székelyhidi, Z. Bánhegyi, Z. Varga, B. Hegymegi-Barakonyi, C. Szántai-Kis, D. Hafenbradl, B. Klebl, G. Müller, A. Ullrich, D. Erös, Z. Horváth, Z. Greff, J. Marosfalvi, J. Pató, I. Szabadkai, I. Szilágyi, Z. Szegedi, I. Varga, F. Wáczek and L. Örfi: Drug discovery in the kinase inhibitory field using the nested chemical libraryTM technology. In: Assay and Drug Development Technologies Assay Drug Dev. Technol., 543-552 (2005).
http://edoc.mpg.de
The Max Planck Society does not take any responsibility for the content of this export.